The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-HAART era among a national managed-care population

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 4, 2004, Pages 972-977

  Mahadevia, Parthiv J ^a   Gebo, Kelly A ^b   Pettit, Krista ^c   Dunn, J P ^b   Covington, Melva T ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

AIDS; Cytomegalovirus retinitis; Economics; Epidemiology; Highly active antiretroviral therapy; HIV

Indexed keywords

CIDOFOVIR; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GENDER; HEALTH CARE COST; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRIORITY JOURNAL; RETINITIS; RETROSPECTIVE STUDY; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; CYTOMEGALOVIRUS RETINITIS; FEMALE; HUMANS; INCIDENCE; INJECTIONS; MALE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 3242673386     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408010-00012     Document Type: Article

References (21)

1. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115-123.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Dunn JP. Cytomegalovirus retinitis in 2003. Hopkins HIV Rep. 2003;15:8-11.
4. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126.
5. Martin DF, Dunn JP, Davis JL, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Ophthalmol. 1999;127:329-339.
6. Piascik P. Fomiversen sodium approved to treat CMV retinitis. J Am Pharm Assoc. 1999;39:84-85.
7. MacDougall DS. Update on cidofovir for CMV retinitis. J Int Assoc Physicians AIDS Care. 1997;3:18-24.
8. Davies L, Maynard A. An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. Int J STD AIDS. 1996;7:415-421.
9. Rachlis A, Smaill F, Walker V, et al. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics. 1999;16:71-84.
10. Lee TA, Sullivan SD, Veenstra, DL, et al. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics. 2001;19:535-550.
11. Sullivan SD, Mozaffari E, Johnson ES, et al. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin Ther. 1996;18:546-558.
12. Griffiths RI, Bleecker GC, Jabs DA, et al. Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics. 1998;13:461-474.
13. Hardens M. Ganciclovir evaluation in AIDS patients with cytomegalovirus retinitis: a European study of treatment patterns and resource utilization. AIDS. 1996;10(suppl 4):S25-S30.
14. Graf von den Schulenburg JM, Wahling S, Stoll M. German health economic cost evaluation on oral ganciclovir in treating cytomegalovirus retinitis. Pharmacoeconomics. 1996;10:522-534.
15. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
16. Desgagne A, Castilloux AM, Angers JF, et al. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13:487-497.
17. Foscamet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-1261.
18. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340:1063-1070.
19. Centers for Disease Control. HIV Outpatient Study Database. Atlanta: Centers for Disease Control; 2003.
20. Fasciano NJ, Cherlow AL, Turner BJ, et al. Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm. Health Care Financ Rev. 1998;19:19-38.
21. Rosenblum L, Buehler JW, Morgan MW, et al. HIV infection in hospitalized patients and Medicaid enrollees: the accuracy of medical record coding. Am J Public Health. 1993;83:1457-1459.